12:00 AM
 | 
Mar 21, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

BRAHMS Copeptin blood test regulatory update

The U.K.'s NICE issued an appraisal consultation document recommending against use of Thermo Fisher's BRAHMS copeptin assay in combination with cardiac troponin testing to rule out myocardial infarction (MI) in patients presenting with acute chest pain. According to the independent Medical Technologies Advisory...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >